Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Total Valuation
Sarepta Therapeutics has a market cap or net worth of $1.96B. The enterprise value is $2.38B.
Market Cap$1.96B
Enterprise Value$2.38B
Share Statistics
Sarepta Therapeutics has 97,713,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,713,440
Owned by Insiders4.14%
Owned by Institutions6.19%
Financial Efficiency
Sarepta Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.06%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)6.06%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.39M
Profits Per Employee171.46K
Employee Count1,372
Asset Turnover0.48
Inventory Turnover0.43
Valuation Ratios
The current PE Ratio of Sarepta Therapeutics is 19.6. Sarepta Therapeutics’s PEG ratio is ―.
PE Ratio19.6
PS Ratio―
PB Ratio―
Price to Fair Value7.57
Price to FCF―
Price to Operating Cash Flow-6.65
PEG Ratio―
Income Statement
In the last 12 months, Sarepta Therapeutics had revenue of 1.90B and earned 235.24M in profits. Earnings per share was 2.34.
Revenue1.90B
Gross Profit1.58B
Operating Income218.08M
Pretax Income260.77M
Net Income235.24M
EBITDA333.06M
Earnings Per Share (EPS)2.34
Cash Flow
In the last 12 months, operating cash flow was -300.75M and capital expenditures -140.79M, giving a free cash flow of -441.55M billion.
Operating Cash Flow-300.75M
Free Cash Flow-441.55M
Free Cash Flow per Share-4.52
Dividends & Yields
Sarepta Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.75
52-Week Price Change-85.59%
50-Day Moving Average18.68
200-Day Moving Average72.38
Relative Strength Index (RSI)54.37
Average Volume (3m)18.21M
Important Dates
Sarepta Therapeutics upcoming earnings date is Oct 29, 2025, After Close (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateOct 29, 2025
Ex-Dividend Date―
Financial Position
Sarepta Therapeutics as a current ratio of 4.20, with Debt / Equity ratio of 99.74%
Current Ratio4.20
Quick Ratio3.18
Debt to Market Cap0.10
Net Debt to EBITDA0.72
Interest Coverage Ratio11.86
Taxes
In the past 12 months, Sarepta Therapeutics has paid 25.54M in taxes.
Income Tax25.54M
Effective Tax Rate0.10
Enterprise Valuation
Sarepta Therapeutics EV to EBITDA ratio is 35.43, with an EV/FCF ratio of -34.43.
EV to Sales6.20
EV to EBITDA35.43
EV to Free Cash Flow-34.43
EV to Operating Cash Flow-57.34
Balance Sheet
Sarepta Therapeutics has $800.14M in cash and marketable securities with $1.35B in debt, giving a net cash position of $553.74M billion.
Cash & Marketable Securities$800.14M
Total Debt$1.35B
Net Cash$553.74M
Net Cash Per Share$5.67
Tangible Book Value Per Share$15.79
Margins
Gross margin is 78.85%, with operating margin of 11.47%, and net profit margin of 12.37%.
Gross Margin78.85%
Operating Margin11.47%
Pretax Margin13.71%
Net Profit Margin12.37%
EBITDA Margin17.51%
EBIT Margin14.68%
Analyst Forecast
The average price target for Sarepta Therapeutics is $24.70, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$24.70
Price Target Upside22.16% Upside
Analyst ConsensusHold
Analyst Count28
Revenue Growth Forecast64.89%
EPS Growth Forecast-221.56%